Innate Pharma (NASDAQ:IPHA) Upgraded to “Strong-Buy” at Evercore ISI

Evercore ISI upgraded shares of Innate Pharma (NASDAQ:IPHA) to a strong-buy rating in a research note issued to investors on Monday morning, Zacks.com reports.

Separately, HC Wainwright restated a buy rating and set a $11.50 price target on shares of Innate Pharma in a report on Friday, September 13th.

Innate Pharma Stock Up 1.8 %

Shares of NASDAQ IPHA opened at $2.21 on Monday. Innate Pharma has a 1-year low of $1.81 and a 1-year high of $3.15. The business’s 50 day moving average is $2.22 and its two-hundred day moving average is $2.39. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.73 and a quick ratio of 3.73.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.